Thermo Fisher Scientific Launches New Biomarker Test In Europe To Rapidly Diagnose Heart Attack

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), commonly known as a heart attack. Copeptin, developed by recently acquired B.R.A.H.M.S.